In the current study, we examined whether genetic polymorphisms in ABCB1, ABCC1, ABCC2, and ABCG2 genes may have an impact on the outcome of CML patients treated with nilotinib. Here, ABCB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.